Protalix files BLA to compete with Sanofi Genzyme; Rallybio collects another Alexion alum
→ Protalix BioTherapeutics has filed a BLA for their Fabry Disease treatment, pegunigalsidase alfa. The drug is a recombinant enzyme …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
